CML HealthCare Inc.'s Subsidiary, Hemostasis Reference Laboratory Awarded Contract Extension with Isis Pharmaceuticals

CML HealthCare Inc.'s Subsidiary, Hemostasis Reference Laboratory Awarded 
Contract Extension with Isis Pharmaceuticals 
MISSISSAUGA, ONTARIO -- (Marketwired) -- 04/19/13 -- CML HealthCare
Inc. (TSX:CLC) (the "Company" or "CML"), a leading community-based
provider of laboratory and medical imaging services in Ontario and
British Columbia, today announced that its subsidiary, Hemostasis
Reference Laboratory Inc. ("HRL") has been awarded a contract
extension to work with Isis Pharmaceuticals ("Isis") on their Factor
XI ("ISIS-FXIRX") Phase II clinical trial. ISIS-FXIRX is an antisense
drug designed to treat clotting disorders. HRL is currently the
coagulation testing laboratory of choice for ISIS-FXIRX Phase I
clinical trial. 
Under the new contract, HRL will be the specialty coagulation
laboratory testing all ISIS-FXIRX Phase II clinical trial samples.
HRL has worked closely with Isis in the past to develop specific
testing panels that would best suit their needs, including reagent
sensitivities for FXI, as well as numerous Thrombin Generation
assays. 
"We are excited to continue strengthening our partnership with ISIS,
a leading antisense drug discovery and development company. HRL's
technical proficiencies in developing customized testing panels will
provide ISIS with the ideal platform to further their clinical
trials," said Thomas Wellner, President and Chief Executive Officer
of CML. "We look forward to continuing to service contract research
organizations, pharmaceutical and biotechnology companies with our
in-depth capabilities and unique service offerings." 
About CML HealthCare Inc. 
Based in Mississauga, Ontario, CML HealthCare Inc. a leading
community-based, medical diagnostic services provider in Canada
operating 114 Client C.A.R.E. Centres in Ontario, 84 imaging centres
in Ontario and British Columbia, and its subsidiary, Hemostasis
Reference Laboratory, a reference laboratory in Ontario focused on
specialized coagulation testing and equipment calibration for
international customers. CML is publicly-traded on the Toronto Stock
Exchange under the symbol "CLC" and has approximately 89.8 million
common shares outstanding. For more information, please visit
www.cmlhealthcare.com or follow CML on Twitter @cmlhealthcare. 
About ISIS-FXIRx 
ISIS-FXIRx is an antis
ense drug discovered and being developed by
Isis Pharmaceuticals. ISIS-FXIRx is designed to treat clotting
disorders by inhibiting the production of Factor XI, a clotting
factor produced in the liver that is an important component of the
coagulation pathway. High levels of Factor XI increase the risk of
thrombosis, a process involving aberrant blood clot formation
responsible for most heart attacks and strokes. Elevated levels of
Factor XI also increase the risk of venous thrombosis, a common
problem after surgery, particularly major orthopedic procedures, such
as knee or hip replacement. People who are deficient in Factor XI
have a lower incidence of thromboembolic events with minimal increase
in bleeding risk.
Contacts:
CML HealthCare Inc.
Alice Dunning, MBA, CFA
Director, Corporate Communications
DunningA@cml.ca
www.cmlhealthcare.com
 
 
Press spacebar to pause and continue. Press esc to stop.